Trials / Unknown
UnknownNCT04220372
Tongxinluo Capsule for Coronary Microvascular Disease
The Efficacy and Safety of Tongxinluo Capsule in Patients With Coronary Microvascular Disease
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy and safety of Tongxinluo in patients with microvascular angina pectoris. Long-term follow-up of 1 to 5 years will be performed to evaluate the effect of Tongxinluo on long-term adverse cardiovascular events in patients with coronary microvascular disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tongxinluo | Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD |
| DRUG | Placebo | Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2021-01-01
- Completion
- 2025-01-01
- First posted
- 2020-01-07
- Last updated
- 2020-01-07
Source: ClinicalTrials.gov record NCT04220372. Inclusion in this directory is not an endorsement.